Our findings suggest that signature genes associated with TREM2+ TAMs, including APOE, SPP1, C1QC, C1QB, and C1QA, can potentially serve as biomarkers for liquid biopsies and immunotherapy modulation in ESCC. The gene discussed is TREM2; the disease is esophageal squamous cell carcinoma.